Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Furihata

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2002
Characterization of human glycoprotein VI gene 5' regulatory and promoter regionsKenichi Furihata, Thomas J Kunicki
Clinical and Experimental Nephrology|February 21, 2020
A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult malesKenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino, et al.
Archives of Pathology & Laboratory Medicine|February 28, 2002
Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosisKenichi Furihata, Diane J Nugent, Thomas J Kunicki
Journal of Clinical Pharmacology|August 5, 2015
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazoleChiyo K Imamura, Kenichi Furihata, Shinichiro Okamoto, et al.
Blood|July 15, 2005
The influence of N-linked glycosylation on the function of platelet glycoprotein VIThomas J Kunicki, Yann Cheli, Masaaki Moroi, et al.
Clinical Pharmacology in Drug Development|January 6, 2022
Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 StudyKenichi Furihata, Izumi Hamada, Takuro Niwa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 10, 2025
Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 DiabetesRisa Nasu, Tomonori Oura, Kenji Ohwaki, et al.
The Journal of Dermatology|August 18, 2025
Phase 1 Study of Topical Administration of Novel Phosphodiesterase-4 Inhibitor PF-07038124 in Japanese Healthy ParticipantsRyosuke Ono, Shinsuke Wada, Nobushige Matsuoka, et al.
Oncology|February 24, 2021
Prediction of Recurrence in Patients with Stage III Colon Cancer Using Conventional Clinicopathological Factors and Peripheral Blood Test Data: A New Analysis with Artificial IntelligenceYutaro Kamei, Tetsuro Takayama, Toshiyuki Suzuki, et al.
Diabetes, Obesity & Metabolism|October 14, 2021
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetesKenichi Furihata, Hanaka Mimura, Shweta Urva, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2002
Characterization of human glycoprotein VI gene 5' regulatory and promoter regionsKenichi Furihata, Thomas J Kunicki
Clinical and Experimental Nephrology|February 21, 2020
A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult malesKenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino, et al.
Archives of Pathology & Laboratory Medicine|February 28, 2002
Influence of platelet collagen receptor polymorphisms on risk for arterial thrombosisKenichi Furihata, Diane J Nugent, Thomas J Kunicki
Journal of Clinical Pharmacology|August 5, 2015
Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazoleChiyo K Imamura, Kenichi Furihata, Shinichiro Okamoto, et al.
Blood|July 15, 2005
The influence of N-linked glycosylation on the function of platelet glycoprotein VIThomas J Kunicki, Yann Cheli, Masaaki Moroi, et al.
Clinical Pharmacology in Drug Development|January 6, 2022
Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 StudyKenichi Furihata, Izumi Hamada, Takuro Niwa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 10, 2025
Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 DiabetesRisa Nasu, Tomonori Oura, Kenji Ohwaki, et al.
The Journal of Dermatology|August 18, 2025
Phase 1 Study of Topical Administration of Novel Phosphodiesterase-4 Inhibitor PF-07038124 in Japanese Healthy ParticipantsRyosuke Ono, Shinsuke Wada, Nobushige Matsuoka, et al.
Oncology|February 24, 2021
Prediction of Recurrence in Patients with Stage III Colon Cancer Using Conventional Clinicopathological Factors and Peripheral Blood Test Data: A New Analysis with Artificial IntelligenceYutaro Kamei, Tetsuro Takayama, Toshiyuki Suzuki, et al.
Diabetes, Obesity & Metabolism|October 14, 2021
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetesKenichi Furihata, Hanaka Mimura, Shweta Urva, et al.
Pageof 5